Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
International Immunopharmacology · 2024-06 · 134 · 112043
DOI: 10.1016/j.intimp.2024.112043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Wojciech Szlasa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lower Silesia Centre for Oncology, Pulmonology and Hematology in Wrocław, 53-439 Wroclaw, Poland; Medical University Hospital, Borowska 213, 50-556, …. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lower Silesia Centre for Oncology, Pulmonology and Hematology in Wrocław, 53-439 Wroclaw, Poland; Medical University Hospital, Borowska 213, 50-556, Wrocław, Poland; Department of Molecular and Cellular Biology, Faculty…
- Lower Silesia Centre for Oncology, Pulmonology and Hematology in Wrocław, 53-439 Wroclaw, Poland; Department of Oncology and Hematology, Wroclaw University of Science and Technology, 50-370 Wrocław, Poland. Electronic a…
Zitieren
APA
Szlasa, W., & Dybko, J. (2024). Current status of bispecific antibodies and CAR-T therapies in multiple myeloma. International Immunopharmacology, 134, 112043. https://doi.org/10.1016/j.intimp.2024.112043
Vancouver
Szlasa W, Dybko J. Current status of bispecific antibodies and CAR-T therapies in multiple myeloma. International Immunopharmacology. 2024;134:112043. doi:10.1016/j.intimp.2024.112043
BibTeX
@article{Szlasa2024,
author = {Szlasa, Wojciech and Dybko, Jarosław},
title = {Current status of bispecific antibodies and CAR-T therapies in multiple myeloma},
journal = {International Immunopharmacology},
year = {2024},
volume = {134},
pages = {112043},
doi = {10.1016/j.intimp.2024.112043}
}
EUVIMED